Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - ustekinumab, quantity: 45 mg - injection, solution - excipient ingredients: water for injections; polysorbate 80; histidine; histidine hydrochloride monohydrate; sucrose - --plaque psoriasis -- adults - wezlana is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,--plaque psoriasis -- paediatric population, 6 years and older - wezlana is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,--psoriatic arthritis (psa) -- wezlana, alone or in combination with methotrexate, is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological dmard therapy has been inadequate.,--crohn?s disease -- wezlana is indicated for the treatment of adult patients with moderately to severely active crohn?s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnfalpha antagonist or have medical contraindications to such therapies.,--ulcerative colitis -- wezlana is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - ustekinumab, quantity: 130 mg - injection, intravenous infusion - excipient ingredients: methionine; sucrose; histidine; water for injections; polysorbate 80; histidine hydrochloride monohydrate; disodium edetate - --crohn?s disease-- wezlana is indicated for the treatment of adult patients with moderately to severely active crohn?s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnf alpha antagonist or have medical contraindications to such therapies.,--ulcerative colitis-- wezlana is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

Australia - English - Department of Health (Therapeutic Goods Administration)

amgen australia pty ltd - ustekinumab, quantity: 90 mg - injection, solution - excipient ingredients: water for injections; sucrose; histidine; polysorbate 80; histidine hydrochloride monohydrate - --plaque psoriasis -- adults - wezlana is indicated for the treatment of adult patients (18 years or older) with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy.,--plaque psoriasis -- paediatric population, 6 years and older - wezlana is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescent patients from 6 years of age who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.,--psoriatic arthritis (psa) -- wezlana, alone or in combination with methotrexate, is indicated for the treatment of signs and symptoms of active psoriatic arthritis in adult patients (18 years and older) where response to previous non-biological dmard therapy has been inadequate.,--crohn?s disease -- wezlana is indicated for the treatment of adult patients with moderately to severely active crohn?s disease who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a tnf alpha antagonist or have medical contraindications to such therapies.,--ulcerative colitis-- wezlana is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

johnson & johnson sdn. bhd. - ustekinumab -

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: johnson & johnson (philippines), inc.; distributor: johnson & johnson (philippines), inc. - ustekinumab - solution for injection (sc) - 90 mg/ml

Philippines - English - FDA (Food And Drug Administration)

johnson & johnson (phils.) inc.; distributor: zuellig pharma corporation - ustekinumab - solution for injection (sc) - 45 mg/0.5ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

janssen-cilag international nv, belgium - ustekinumab - solution for injection in pre-filled syringe - 130 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

janssen-cilag international nv, belgium - ustekinumab - solution for injection in pre-filled syringe - 90 mg/ml

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

janssen-cilag international nv, belgium - ustekinumab - solution for injection in pre-filled syringe - 90 mg/ml

Philippines - English - FDA (Food And Drug Administration)

johnson & johnson (phils.) inc.; distributor: zuellig pharma corporation - ustekinumab - solution for injection - 45mg/ 0.5ml